

Joshua M Lang

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2846943/joshua-m-lang-publications-by-citations.pdf>

Version: 2023-06-07

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48
papers

975
citations

15
h-index

30
g-index

52
ext. papers

1,279
ext. citations

6.9
avg, IF

4.09
L-index

#	Paper	IF	Citations
48	Augmenting antitumor immune responses with epigenetic modifying agents. <i>Frontiers in Immunology</i> , 2015 , 6, 29	2	119
47	Pilot trial of interleukin-2 and zoledronic acid to augment T cells as treatment for patients with refractory renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1447-60	1.6	92
46	Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. <i>Clinical Cancer Research</i> , 2017 , 23, 4704-4715	3	90
45	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018 , 73, 715-723	2.3	71
44	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020 , 52, 778-789	7	71
43	The VerIFAST: an integrated method for cell isolation and extracellular/intracellular staining. <i>Lab on A Chip</i> , 2013 , 13, 391-6	2.2	53
42	High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1. <i>PLoS ONE</i> , 2016 , 11, e0159397	1.2	45
41	A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. <i>Methods</i> , 2013 , 64, 137-43	1.5	41
40	Circulating tumor cells: getting more from less. <i>Science Translational Medicine</i> , 2012 , 4, 141ps13	5.2	41
39	Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation. <i>Clinical Cancer Research</i> , 2017 , 23, 746-756	3	39
38	Selective nucleic acid removal via exclusion (SNARE): capturing mRNA and DNA from a single sample. <i>Analytical Chemistry</i> , 2013 , 85, 9764-70	2.7	33
37	Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements. <i>Lab on A Chip</i> , 2014 , 14, 24-31	2.2	25
36	Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform. <i>Lab on A Chip</i> , 2014 , 14, 99-105	2.2	20
35	Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. <i>Journal of Urology</i> , 2018 , 199, 1494-1501	0.6	17
34	Surface topography and hydrophilicity regulate macrophage phenotype in milled microfluidic systems. <i>Lab on A Chip</i> , 2018 , 18, 3011-3017	2.2	17
33	Integration of Magnetic Bead-Based Cell Selection into Complex Isolations. <i>ACS Omega</i> , 2018 , 3, 3908-3917	1.1	15
32	Regulation of inside-out β -integrin activation by CDCP1. <i>Oncogene</i> , 2018 , 37, 2817-2836	2.5	14

31	Inducible expression of cancer-testis antigens in human prostate cancer. <i>Oncotarget</i> , 2016 , 7, 84359-84374	1.4	14
30	Exclusive Liquid Repellency: An Open Multi-Liquid-Phase Technology for Rare Cell Culture and Single-Cell Processing. <i>ACS Applied Materials & Interfaces</i> , 2018 , 10, 17065-17070	3.1	13
29	Prioritization of cancer antigens: keeping the target in sight. <i>Expert Review of Vaccines</i> , 2009 , 8, 1657-611.8	1.8	13
28	A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 407-15	0.8	11
27	Pazopanib for the treatment of patients with advanced renal cell carcinoma. <i>Clinical Medicine Insights: Oncology</i> , 2010 , 4, 95-105	0.4	10
26	Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extraction. <i>Lab on A Chip</i> , 2018 , 18, 3446-3458	2.2	10
25	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2926-2937	0.7	10
24	Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. <i>JCO Precision Oncology</i> , 2017 , 1,	1.1	9
23	Exploring Spatial-Temporal Changes in F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3662-3671	0.7	8
22	Automated System for Small-Population Single-Particle Processing Enabled by Exclusive Liquid Repellency. <i>SLAS Technology</i> , 2019 , 24, 535-542	0.7	7
21	Centrifugation-Assisted Immiscible Fluid Filtration for Dual-Bioanalyte Extraction. <i>Analytical Chemistry</i> , 2019 , 91, 11848-11855	2.7	7
20	Development and translation of novel therapeutics targeting tumor-associated macrophages. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 556-562	0.7	7
19	Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. <i>Urology</i> , 2017 , 100, 139-144	0.3	5
18	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. <i>Clinical Cancer Research</i> , 2021 , 27, 3610-3619	3	5
17	A role for microfluidic systems in precision medicine. <i>Nature Communications</i> , 2022 , 13,	5	5
16	Pairing Microwell Arrays with an Affordable, Semiautomated Single-Cell Aspirator for the Interrogation of Circulating Tumor Cell Heterogeneity. <i>SLAS Technology</i> , 2020 , 25, 162-176	0.7	4
15	Centrosome amplification is a frequent event in circulating tumor cells from subjects with metastatic breast cancer. <i>Molecular Oncology</i> , 2020 , 14, 1898-1909	2	4
14	Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies. <i>Immunotherapy</i> , 2013 , 5, 1243-54	0.9	4

13	Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. <i>Molecular Oncology</i> , 2021 , 15, 2330-2344	2	4
12	Vital ex vivo tissue labeling and pathology-guided micropunching to characterize cellular heterogeneity in the tissue microenvironment. <i>BioTechniques</i> , 2018 , 64, 13-19	0.8	4
11	BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity. <i>Nucleic Acids Research</i> , 2021 , 49, 12211-12233	4.4	3
10	Are liquid biopsies ready for primetime?. <i>Cancer</i> , 2019 , 125, 834-837	1.7	2
9	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021 , 7, 1644-1652	3.2	2
8	Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling. <i>Medical Oncology</i> , 2021 , 38, 135	0.8	2
7	Understanding dynamic interactions in the prostate tumor microenvironment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 532-534	0.7	1
6	Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides. <i>American Journal of Clinical and Experimental Urology</i> , 2019 , 7, 215-222	0.3	1
5	AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer. <i>Endocrine-Related Cancer</i> , 2021 , 28, 645-655	1	0
4	SEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples.. <i>Clinical Epigenetics</i> , 2022 , 14, 37	1.8	0
3	Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer.. <i>Biomarker Research</i> , 2022 , 10, 26	3	0
2	Reply to M. K. Bos et al. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102238	0.7	
1	Directing Circulating Tumor Cell Technologies Into Clinical Practice 2016 , 351-364		